Monoclonal antibody therapy

Genmab Announces Enapotamab Vedotin Update

Retrieved on: 
Tuesday, November 24, 2020
Genmab, Monoclonal antibodies, Medical specialties, SeaGen, Health care, Pharmaceutical companies, HuMax, Monomethyl auristatin E, Monoclonal antibody therapy

Copenhagen, Denmark; November 24, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it will not advance the development of enapotamab vedotin.

Key Points: 
  • Copenhagen, Denmark; November 24, 2020 Genmab A/S (Nasdaq: GMAB) announced today that it will not advance the development of enapotamab vedotin.
  • While enapotamab vedotin has shown some evidence of clinical activity, this was not optimized by different dose schedules and/or predictive biomarkers.
  • Enapotamab vedotin is fully owned by Genmab and the drug linker technology used for enapotamab vedotin was licensed from Seagen Inc.
    Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
  • Genmab A/S and/or its subsidiaries own the following trademarks: Genmab; the Y-shaped Genmab logo; Genmab in combination with the Y-shaped Genmab logo; HuMax; DuoBody; DuoBody in combination with the DuoBody logo; HexaBody; HexaBody in combination with the HexaBody logo; DuoHexaBody; HexElect; and UniBody.

CARsgen Therapeutics to Present Multiple Myeloma Cell Therapy Data at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition in December

Retrieved on: 
Friday, November 20, 2020
Clinical medicine, Medicine, Medical specialties, Cancer immunotherapy, Chimeric antigen receptor T cell, Gene therapy, Immune system, Lymphoma, Multiple myeloma, Monoclonal antibody therapy, Adoptive cell transfer, David G. Maloney

CT053 is an investigational anti-BCMA (B cell maturation antigen) autologous chimeric antigen receptor (CAR) T-cell product for the treatment of adult patients with relapsed and/or refractory multiple myeloma.

Key Points: 
  • CT053 is an investigational anti-BCMA (B cell maturation antigen) autologous chimeric antigen receptor (CAR) T-cell product for the treatment of adult patients with relapsed and/or refractory multiple myeloma.
  • These are open-label, multicenter studies evaluating the safety and efficacy of CT053 in adult patients with relapsed and/or refractory multiple myeloma.
  • CARsgen Therapeutics is a clinical-stage immuno-oncology company committed to the development of first-in-class and best-in-class CAR T-cell and antibody therapeutics.
  • CARsgen also has ongoing clinical CAR T-cell programs with a humanized CAR-CD19 for leukemia and lymphoma.

Abzyme Files Patent Application for pH-dependent anti-CD3 Antibodies

Retrieved on: 
Tuesday, November 17, 2020
Biotechnology, Pharmaceutical, Health, Oncology, Medical specialties, Immunology, Clinical medicine, Immune system, Abzyme, Enzymes, Antibody, Monoclonal antibody therapy

Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled "Antibodies Binding to Human CD3 at Acidic pH, USPTO number 63/109,005.

Key Points: 
  • Abzyme Therapeutics LLC, a biotech company focused on developing antibodies for diagnostic and therapeutic applications, has filed a patent application entitled "Antibodies Binding to Human CD3 at Acidic pH, USPTO number 63/109,005.
  • This patent application is an important step forward for Abzyme Therapeutics solidifying its intellectual property position in the field of therapeutic antibody development.
  • These antibodies are able to activate T cells at acidic pH while having significantly reduced activity at neutral or physiological pH.
  • As we pride ourselves as innovators, we are extremely pleased to achieve this milestone filing this application said Dr. Tran, CEO and co-founder of Abzyme.

Merus to Present at the Jefferies Virtual London Healthcare Conference

Retrieved on: 
Monday, November 16, 2020
Immunology, Branches of biology, Antibody, Monoclonal antibody therapy, Biology

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonicsand Triclonics), today announced thatBill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference onTuesday, November 17, 2020at14:40 p.m. GMT/9:40 a.m.

Key Points: 
  • UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonicsand Triclonics), today announced thatBill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference onTuesday, November 17, 2020at14:40 p.m. GMT/9:40 a.m.
  • A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl/ .
  • An archived presentation will be available on the Merus website for a limited time.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics.

Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer

Retrieved on: 
Monday, November 9, 2020
Medical specialties, Immunology, Clinical medicine, Medicine, CD137, Monoclonal antibody therapy, PD-L1

We look forward to sharing data on MCLA-145, our clinical stage Biclonics bispecific antibody directed at CD137 on T cells and PD-L1 on cancer cells, said Andrew Joe, M.D., Chief Medical Officer of Merus.

Key Points: 
  • We look forward to sharing data on MCLA-145, our clinical stage Biclonics bispecific antibody directed at CD137 on T cells and PD-L1 on cancer cells, said Andrew Joe, M.D., Chief Medical Officer of Merus.
  • In preclinical studies, MCLA-145 demonstrates potent anti-tumor effect and does not appear to exhibit the safety liabilities that have been observed with other potent CD137 agonists.
  • Posters will be on display from Monday, November 9, 2020 until the virtual poster hall closes on December 31, 2020.
  • Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics.

CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 5, 2020
Life sciences, Biotechnology, Health sciences, Bristol Myers Squibb, Specialty drugs, Monoclonal antibody therapy, Biopharmaceutical

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform, today reported third quarter 2020 financial results and provided a business update.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody technology platform, today reported third quarter 2020 financial results and provided a business update.
  • CytomX expects to initiate a redesigned, multi-arm Phase 2 study evaluating CX-2009, a first in class anti-CD166 Probody drug conjugate, in patients HER2 negative breast cancer, in the fourth quarter of 2020.
  • An archive of the webcast will be available on the CytomX website from November 5, 2020, until November 12, 2020.
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
    Opdivo is a registered trademark of Bristol Myers Squibb.

CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

Retrieved on: 
Thursday, November 5, 2020
Medical specialties, Clinical medicine, Medicine, Immunology, AbbVie, Monoclonal antibody therapy, Monomethyl auristatin E, Transferrin receptor 1, Antibody-drug conjugate

In April 2016, AbbVie and CytomX entered into a Co-Development and Licensing Agreement under which the two companies are co-developing CX-2029, a Probody drug conjugate against CD71 conjugated to the cytotoxic payload MMAE.

Key Points: 
  • In April 2016, AbbVie and CytomX entered into a Co-Development and Licensing Agreement under which the two companies are co-developing CX-2029, a Probody drug conjugate against CD71 conjugated to the cytotoxic payload MMAE.
  • We are developing a novel class of investigational antibody therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • The CytomX clinical stage pipeline includes first-in-class product candidates against previously undruggable targets, including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009) and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029).
  • Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.

CytomX Therapeutics to Announce Third Quarter 2020 Financial Results

Retrieved on: 
Thursday, October 29, 2020
Life sciences, Health sciences, Biotechnology, Pharmaceutical industry, Pharmacy, Specialty drugs, Biopharmaceutical, Therapy, Tumor microenvironment, Monoclonal antibody therapy, Halozyme, Inc.

An archived webcast replay will be available on the Company's website from November 5, 2020, until November 12, 2020.

Key Points: 
  • An archived webcast replay will be available on the Company's website from November 5, 2020, until November 12, 2020.
  • CytomX is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies.
  • We are developing a novel class of investigational antibody therapeutics, based on our Probody technology platform, for the treatment of cancer.
  • Probody therapeutics are designed to remain inactive until they are activated by proteases in the tumor microenvironment.

OSE Immunotherapeutics Announces Publication Supporting Additional New Mechanism of Action for Selective Antibody Antagonist of SIRPα BI 765063 in the Journal of Clinical Investigation

Retrieved on: 
Thursday, October 22, 2020
Clinical medicine, Medicine, Medical specialties, Boehringer Ingelheim, Immunology, Immune system, Cancer immunotherapy, Immunotherapy, Monoclonal antibody, Compugen, Monoclonal antibody therapy

BI 765063 is currently being evaluated in a Phase 1 clinical trial conducted in patients with advanced solid tumors.

Key Points: 
  • BI 765063 is currently being evaluated in a Phase 1 clinical trial conducted in patients with advanced solid tumors.
  • OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • BI 765063 (OSE-172, anti-SIRP monoclonal antibody): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.
  • Positive preclinical and human ex vivo results in August 2020, clinical trial expected to start end of 2020/early 2021.

Antibody Discovery Services and Platforms Market, 2030 - 80 Monoclonal Antibodies Approved to Date & 550+ Molecules in the Clinical Pipeline

Retrieved on: 
Wednesday, October 21, 2020
Medical specialties, Clinical medicine, Immunology, Medicine, Biotechnology, Antibody, Monoclonal antibody therapy, Monoclonal antibody, Bispecific monoclonal antibody, Biopharmaceutical, Antibody Solutions, Antibody-oligonucleotide conjugate

The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics.

Key Points: 
  • The study underlines an in-depth analysis of the antibody discovery technologies and services that assist in the development of antibody therapeutics.
  • One of the key objectives of the report was to estimate the existing market size and potential future opportunities for antibody discovery platforms and services, for the next decade.
  • With close to 80 monoclonal antibodies approved till date, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become an important part of the biopharmaceutical industry.
  • Further, given the success of monoclonal antibodies, research on other novel antibody formats, such as bispecific antibodies, antibody drug conjugates (ADCs) and antibody fragments, has also gained traction.